ArticleAdvances in urology2012
Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy.
Article in Advances in urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Perceptions of partial gland ablation for prostate cancer among men on active surveillance: A qualitative study.BMJ surgery, interventions, & health technologies · 2021Article
- Transperineal versus transrectal multi-parametric magnetic resonance imaging fusion targeted prostate biopsy.Saudi medical journal · 2021Article
- Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.Virchows Archiv : an international journal of pathology · 2018Article
- MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.Cell death & disease · 2018Article
- SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.Oncotarget · 2016Article
- Initial Experience of Targeted Focal Interstitial Laser Ablation of Prostate Cancer with MRI Guidance.Current urology · 2015Article
- Radical prostatectomy specimens - a voice against focal therapy.Central European journal of urology · 2014Article
- The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach.Advances in urology · 2013Article
- WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone.PloS one · 2013Article
- Human chorionic gonadotropin β induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells.PloS one · 2013Article
- The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.Prostate cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among men, prostate cancer has a high prevalence, with relatively lower cancer-specific mortality risk compared to lung and colon cancer. Prostate-specific antigen (PSA) screening has increased prostate cancer awareness since its implementation as a screening tool almost 25 years ago, but, due to the largely indolent course of this disease and the unspecific nature of the PSA test, increased incidence has largely been associated with cancers that would not go on to cause death (clinically insignificant), leading to an overdiagnosis challenge and an ensuing overtreatment consequences. The overtreatment problem is exacerbated by the high risk of side effects that current treatment techniques have, putting patients' quality of life at risk with little or no survival benefit. The goals of this paper are to evaluate the rise, prevalence, and impact of the overdiagnosis and ensuing overtreatment problems, as well as highlight potential solutions. In this effort, a review of major epidemiological and screening studies, cancer statistics from the advent of prostate-specific antigen screening to the present, and reports on patient concerns and treatment outcomes was conducted to present the dominant factors that underlie current challenges in prostate cancer treatment and illuminate potential solutions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.